Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.